Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101 Sep 06, 2018
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018 Sep 04, 2018
Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Aug 30, 2018
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Aug 14, 2018
Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Aug 13, 2018
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer Aug 13, 2018
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency Aug 13, 2018
Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Aug 09, 2018
